培维索孟(Pegvisomant) - 药物靶点：GHR_在研适应症：肢端肥大症，胰岛素抵抗_专利_临床

概要

基本信息

药物类型

多肽激素

别名

pegviosomant、Pegvisomant (genetical recombination) (JAN)、Pegvisomant (USAN/INN)

+ [7]

靶点

GHR

作用方式

拮抗剂

作用机制

GHR拮抗剂(生长激素受体拮抗剂)

治疗领域

神经系统疾病内分泌与代谢疾病皮肤和肌肉骨骼疾病+ [1]

在研适应症

肢端肥大症胰岛素抵抗

非在研适应症

晚期恶性实体瘤白蛋白尿乳腺癌+ [5]

原研机构

Sensus USA, Inc.

在研机构

Pfizer SRLPharmacia & Upjohn LLCPfizer Europe MA EEIG

+ [2]

非在研机构

Pfizer Ltd.

权益机构-

最高研发阶段批准上市

首次获批日期

欧盟 (2002-11-12),

肢端肥大症

最高研发阶段(中国)-

特殊审评孤儿药 (美国)、孤儿药 (日本)、孤儿药 (韩国)

登录后查看时间轴

结构/序列

Sequence Code 61626

来源: *****

关联

39

项与培维索孟相关的临床试验

NCT05470504

/ Recruiting临床2期IIT

Phase II Study of Growth Hormone Inhibition Using Pegvisomant In Severe Insulin Resistance

Background:
Lipodystrophy (LD) syndromes are a group of rare disorders that affect how a person s body can store and use fat tissue. Many people with LDs become severely insulin resistant. Some people are insulin resistant because of a variant in the insulin receptor gene. Insulin resistance causes many health problems.
Objective:
To learn if blocking the effects of growth hormone in the body will help people with severe insulin resistance.
Eligibility:
Adults aged 18 to 65 years with either a known variant in the insulin receptor gene or with a diagnosis of partial LD.
Design:
Participants will have 2 hospital stays, about 1 month apart. Each stay will be 3 or 4 nights.
During each hospital stay, participants will have many tests. They will have a physical exam with blood tests. They will have all of their urine collected for a 24-hour period. They will have scans to measure their muscle, bone, and fat tissues. They will have tests to measure metabolism and insulin sensitivity. They may have an optional biopsy of fat tissue.
During the first hospital visit, participants will learn how to give themselves shots of a drug (pegvisomant) that blocks growth hormone. The drug is injected under the skin. Participants will continue to give themselves these shots once a day at home.
After the first hospital visit, participants will talk on the phone with members of the study team once each week. After 2 weeks they will have blood drawn for tests.
Participants will stop the shots after the second hospital visit.

开始日期2023-01-23

申办/合作机构

National Institute of Diabetes & Digestive & Kidney Diseases

NCT05131100

/ RecruitingN/A

Korean Post-marketing Surveillance for Somavert

Non-interventional observational study, to identify safety and effectiveness of Somavert during the post-marketing period based on the Korean RMP as required by the regulations of Ministry of Food and Drug Safety (MFDS)

开始日期2022-07-13

申办/合作机构

Pfizer Inc.

CTIS2024-518214-11-01

/ Recruiting临床2期IIT

InvestiGating the rOle of Growth Hormone in hepatic lipid metabolism in humans

开始日期2022-01-01

申办/合作机构

Medical University of Vienna

100 项与培维索孟相关的临床结果

登录后查看更多信息

100 项与培维索孟相关的转化医学

登录后查看更多信息

100 项与培维索孟相关的专利（医药）

登录后查看更多信息

452

项与培维索孟相关的文献（医药）

2026-12-31·JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness of pasireotide long-acting release in acromegaly: a systematic literature review and methodology assessment

Review

作者: Kossi, Sika Dédé ; Bronikowska, Małgorzata ; Schmidt, Fabian ; Gilis-Januszewska, Aleksandra ; Gueron, Beatrice ; Binowski, Grzegorz ; Jachimowicz, Michał

BACKGROUND:

Acromegaly is a rare and progressive condition caused by excessive secretion of growth hormone and insulin-like growth factor type 1. Pasireotide long-acting release (LAR) is indicated as a second-line therapy for adults with acromegaly who are unsuitable for or unresponsive to surgery and inadequately controlled with first-generation somatostatin receptor ligands (FGSRLs). Although its efficacy and safety have already been established, its cost-effectiveness remains unclear. The primary objective of this study was to systematically assess the cost-effectiveness of pasireotide LAR compared to other second-line medical options, particularly pegvisomant.

METHODS:

A systematic literature review was conducted in May 2024 in Medline, Medline In Process, Web of Science, and the Centre for Reviews and Dissemination (CRD), York. Studies were eligible if they were full or partial economic analyses of pasireotide LAR as a second-line pharmacological treatment for adult patients with acromegaly. Studies not available in English and publications prior to 2009 were excluded. Included articles were assessed for transparency using the appropriate checklists. Data extraction focused on costs, incremental cost-effectiveness ratios and quality-adjusted life years. Formal data synthesis of outcomes was not undertaken due to the small number of studies and notable heterogeneity between them. Methodological assessment involving the evaluation of model inputs, data sources, and their alignment with the evidence on the course of disease and clinical practice was performed to examine the main factors contributing to discrepancies in cost-effectiveness outcomes and assess the credibility of the results.

RESULTS:

Of 160 records identified, six publications met the inclusion criteria. Their findings demonstrated variability. The critical assessment highlighted considerable variability in methodological rigor among the included studies.

CONCLUSIONS:

Evidence on pasireotide LAR's cost-effectiveness versus pegvisomant regimens remains inconclusive. Although two studies indicated that pegvisomant is more cost-effective, the study with the highest methodological credibility found that pasireotide LAR is a cost-effective alternative.

2026-04-01·ANNALES D ENDOCRINOLOGIE

Genome architecture in endocrine diseases: X-linked acrogigantism (X-LAG) syndrome

Article

作者: Daly, Adrian F ; Pétrossians, Patrick ; Beckers, Albert

X-linked acrogigantism (X-LAG) is a rare disease that represents a severe form of pituitary gigantism characterized by early-onset growth hormone (GH), insulin-like growth factor 1 (IGF1) and prolactin excess. X-LAG is associated with duplications involving the gene GPR101 on chromosome Xq26.3. Clinically, X-LAG manifests in infancy, with a median age at onset of 18 months, presenting as rapid linear growth, acral enlargement, and large pituitary macroadenomas. While predominantly a sporadic disease affecting females through constitutional duplications, somatic mosaicism is found in sporadic male cases. Three familial cases of X-LAG have been described. Management is difficult due to the young age of affected patients and the relative resistance of GH excess to somatostatin analogs. Multimodal therapy, including neurosurgery and medical therapy such as pegvisomant, is often required to achieve hormonal control and limit final adult height. Unlike other genetic forms of pituitary tumorigenesis that are due to sequence-based mutations, X-LAG is caused by structural changes in 3D genome architecture. Specifically, microduplications on chromosome Xq26.3 disrupt a topologically associating domain (TAD) containing GPR101. This process facilitates the formation of a "neoTAD", where the GPR101 promoter is driven by ectopic enhancers, primarily an intronic enhancer located within the VGLL1 gene, leading to massive pituitary upregulation of this constitutively active receptor and GH excess. X-LAG is an example of how novel disease mechanisms can explain the molecular dysregulation behind rare and difficult to manage endocrine pathologies.

2026-03-06·ENDOCRINOLOGY

A helical peptide antagonist of the human growth hormone receptor

Article

作者: Basu, Reetobrata ; Kopchick, John J ; Nahar, Khairun ; Holub, Justin M ; Ahmad, Arshad ; Gamage, Udani ; Pettis, Joseph A

Abstract:

The binding of human growth hormone (hGH) to the human growth hormone receptor (hGHR) is a key endocrinological process that controls critical aspects of cell growth, proliferation, and differentiation. Mechanistically, this sequential, asymmetric binding event involves the interaction between a single hGH molecule and distinct sites (sites 1 and 2) on the extracellular domain of a preformed hGHR homodimer. Our group recently identified S1H, a rationally designed peptide sequence mimetic of the hGH site 1-binding helix (residues 36-51) that disrupts the hGH-hGHR interaction and inhibits hGH-mediated phosphorylation of signal transducer and activator of transcription 5 (STAT5) in hGHR-positive cell lines. Structure–activity relationship studies revealed a positive correlation between helical propensity and inhibitory potency of the S1H peptide, prompting the design of structurally “stabilized” S1H variants (SS1H) with improved biological activity. In this study, we employed a chemical strategy, termed hydrocarbon stapling, to generate a series of SS1H peptides that proved to be more helical, proteolytically stable, and biologically active compared to linear (unstructured) S1H. Notably, one SS1H derivative (SS1HB) inhibited hGH-induced STAT5 phosphorylation in hGHR-positive human bladder cancer cells more effectively than pegvisomant, the only hGHR antagonist currently approved by the FDA. Collectively, our results demonstrate that hydrocarbon stapling improves the antagonistic effects of S1H peptides and elevates their potential as chemical probes to study the molecular mechanisms of hGH signaling. It is also anticipated that SS1H peptides will serve as potent lead compounds for developing next-generation therapeutics designed to treat endocrine disorders that manifest along the hGH-hGHR signaling axis.

5

项与培维索孟相关的新闻（医药）

2026-04-28

·allsci.com

Crinetics’ Palsonify adds EU approval for acromegaly

The European Commission has approved Palsonify (paltusotine) for the treatment of acromegaly in adults, making it the first once-daily oral therapy authorized for the condition across the 27 EU member states and three European Economic Area countries. The decision marks Crinetics Pharmaceuticals’ first regulatory approval outside the United States and establishes paltusotine, a nonpeptide somatostatin receptor type 2 (SST2) agonist, as the first oral agent in its mechanistic class to reach patients in the EU. The EC approval covers the medical treatment of adult patients with acromegaly and is valid across all EU member states. Crinetics said initial commercialization efforts are planned for Germany and Austria. The drug carries Orphan Drug Designation in the EU. In the US, the FDA had previously approved Palsonify for first-line treatment of adults with acromegaly who had an inadequate response to surgery or for whom surgery is not an option. The EU label, as described in the source material, applies more broadly to medical treatment of acromegaly in adults without specifying a surgical history requirement in the same terms. The EC decision was supported by data from two pivotal Phase III studies, PATHFNDR-1 and PATHFNDR-2, which evaluated paltusotine in previously treated and medically untreated adults with acromegaly, respectively. Across both trials, the company said paltusotine demonstrated rapid onset and sustained biochemical control, with IGF-1 — the primary biomarker used to manage acromegaly — used as the central efficacy measure. PATHFNDR-1 assessed patients switching from monthly injectable somatostatin receptor ligands, while PATHFNDR-2 enrolled treatment-naive patients. Patient-reported outcomes were captured using the Acromegaly Symptom Diary, a validated instrument measuring symptoms including headaches, joint pain, sweating, and fatigue. Treatment was described as generally well-tolerated, with no serious adverse events reported in the randomized controlled portions of the trials. The most common adverse reactions were gastrointestinal, including diarrhea, abdominal pain, nausea, and abdominal discomfort. Acromegaly is a rare endocrine disorder driven predominantly by growth hormone-secreting pituitary adenomas, with excess IGF-1 production as the downstream consequence. The existing standard of care relies heavily on injectable somatostatin receptor ligands such as octreotide and lanreotide, administered monthly, alongside pegvisomant and dopamine agonists. An oral formulation of octreotide, Mycapssa, holds FDA approval for acromegaly maintenance, but paltusotine represents a distinct mechanistic approach as a nonpeptide SST2 agonist rather than a peptide-based agent. The EU approval places Palsonify into a treatment landscape where injectable administration has long been the norm, and where a subset of patients experience incomplete biochemical control or tolerability issues with existing therapies. Crinetics is also advancing paltusotine in Phase III development for carcinoid syndrome associated with neuroendocrine tumors through the CAREFNDR trial, and a new drug application has been submitted in Japan by partner Sanwa Kagaku Kenkyusho, with a marketing authorization application also filed in Brazil. The EU approval is Crinetics’ first international authorization following the US FDA clearance. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

2025-07-14

·PipelineReview

Marea Therapeutics Presents Preclinical Data on Novel Growth Hormone Receptor Antagonist Antibody, MAR002, for the Treatment of Acromegaly at ENDO 2025

SOUTH SAN FRANCISCO, CA, USA I July 14, 2025 I Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced the presentation of preclinical data on MAR002, a novel growth hormone receptor (GHR) antagonist antibody for the treatment of acromegaly, at the 2025 Annual Meeting of the Endocrine Society (ENDO). The oral presentation, titled “Development of a Novel Growth Hormone Receptor Antagonist Antibody for the Treatment of Acromegaly,” highlights the significant potential of MAR002 to address critical unmet needs in patients suffering from this rare and highly morbid disease. Presentation highlights include: Marea Therapeutics has completed a GLP-toxicology study to assess MAR002’s safety. The preclinical pharmacology data strongly support advancing MAR002 into clinical development; a Phase 1 first-in-human study is expected to begin in the third quarter of 2025. Marea’s development strategy aims for rapid advancement into acromegaly patients after achieving proof of mechanism in healthy volunteers, with a clear path to approval guided by FDA guidance for IGF-1 normalization. “The preclinical data presented at ENDO 2025 underscore the potential of MAR002 to meaningfully transform the treatment landscape for acromegaly,” said Ethan Weiss, M.D., chief scientific officer of Marea Therapeutics. “With its strong potency, enhanced durability, and favorable developability profile, MAR002 is uniquely positioned to overcome the limitations of current therapies and offer a more effective, targeted approach for patients. We are excited to advance MAR002 into clinical development and bring forward a next generation and potential best-in-class GHR antagonist.” Marea Therapeutics believes MAR002 represents a significant opportunity to replace and expand the market for existing growth hormone receptor antagonists (GHRAs) and could also be used in combination with somatostatin receptor ligands (SRLs), offering a more effective and convenient treatment option for patients with acromegaly. About MAR002 MAR002 is a novel, potent and selective half-life-extended, allosteric, human monoclonal GHRA antibody being developed for the treatment of acromegaly. The PK and PD properties of MAR002 are predictable and typical of a half-life extended human antibody, showing a long duration of action compatible with infrequent subcutaneous dose administration in humans. These characteristics support its potential to offer an effective and convenient treatment for patients with acromegaly. About Acromegaly Acromegaly is an orphan disease characterized by the excess secretion of growth hormone (GH) from a benign pituitary adenoma. Acromegaly affects approximately 30,000 patients in the U.S. If left untreated, acromegaly is highly morbid, leading to significant comorbidities such as GH-induced insulin resistance and diabetes, and serious cardiovascular pathology. The median lifespan of patients can be shortened by 10 years without effective therapy, and incomplete IGF-1 normalization is associated with increased mortality. Despite its severity, acromegaly is often under or misdiagnosed, with an average time from symptom onset to diagnosis of approximately eight years. The current treatment paradigm for acromegaly often involves surgery, performed in over 90% of patients, which achieves remission in about 50% of cases, though this can degrade over time. Medical therapy is required for approximately 65% (around 20,000 in the U.S.) of patients during their disease journey, regardless of their surgical history. Current medical treatments include somatostatin receptor ligands (SRLs) and growth hormone receptor antagonists (GHRAs), such as pegvisomant. However, many patients do not achieve biochemical control with existing therapies. About Marea Therapeutics Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases. The company’s lead therapy, MAR001, is in Phase 2 clinical development for adults with metabolic dysfunction and high risk for atherosclerotic cardiovascular disease. The company is also advancing MAR002 for the treatment of acromegaly. To learn more, please visit www.mareatx.com and follow us on LinkedIn and X . SOURCE: Marea Therapeutics

临床2期孤儿药临床1期

2024-05-30

·蒲公英Ouryao

又有35个品规儿童药鼓励研发申报

转自：国家卫健委编辑：水晶5月30日，国家卫健委药物政策与基本药物制度司公示第五批鼓励研发申报儿童药品建议清单。公示清单共35个品规，这些品规是国内未注册上市且临床急需的儿童用药。35个第五批公示品规：阿尼芬净（注射剂）、柯拉特龙（乳膏剂）、头孢罗膦（注射剂）、艾伐卡托（颗粒剂）、阿托伐他汀混悬剂、达比加群酯（微丸）、索利那新（混悬剂）、托吡酯（口服溶液剂）、托法替布（口服溶液剂）、西替利嗪（注射剂）、伊伐雷定（口服溶液剂）、氨曲南（吸入溶液剂) 、甲苯磺酸托氟沙星（颗粒剂、片剂）、美替拉酮（胶囊剂）、谷卡匹酶（注射剂）、舒噻美（口服混悬液）、匹莫齐特（片剂）、培维索孟（注射液）、阿昔单抗（注射剂）、瑞斯利珠单抗（注射剂）、卡拉西珠单抗（注射剂）、艾哌依卡基（注射剂）、瑞利珠单抗（注射剂）。第四批24个品种：涉及30个品规、9种剂型，覆盖神经系统用药、消化道和新陈代谢用药、抗肿瘤药及免疫调节剂等治疗领域。<<详见24个品种！四部门联合印发（第四批）鼓励研发申报儿童药品清单>>前三批105种：2016年以来，国家卫生健康委会同有关部门，先后制定并发布了三批含105种药品的《鼓励研发申报儿童药品清单》。为进一步落实原国家卫生计生委等6部门《关于保障儿童用药的若干意见》要求，丰富儿童适用药品的品种、剂型和规格，满足儿科临床用药需求，2024年，国家卫生健康委、工业和信息化部和国家药监局继续紧密围绕我国儿童疾病谱以及相关企业研发生产能力，组织临床、药学、研发、注册等有关专家结合中国大陆境内尚未注册上市且临床急需的儿童用药现状，基于循证原则筛选论证，提出了《第五批鼓励研发申报儿童药品建议清单》。现予以公示，公示5个工作日。如有异议，请通过以下电话予以反映。电话：（010）68791740 附件：第五批鼓励研发申报儿童药品建议清单药物政策与基本药物制度司 2024年5月30日

上市批准

100 项与培维索孟相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05394	培维索孟	H01AX01	DB00082

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
肢端肥大症	欧盟	Pfizer Europe MA EEIG	2002-11-12
肢端肥大症	冰岛	Pfizer Europe MA EEIG	2002-11-12
肢端肥大症	列支敦士登	Pfizer Europe MA EEIG	2002-11-12
肢端肥大症	挪威	Pfizer Europe MA EEIG	2002-11-12

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胰岛素抵抗	临床3期	意大利	Pfizer SRL	2015-12-04
白蛋白尿	临床2期	捷克	Pfizer Ltd.	2004-11-12
糖尿病肾病	临床2期	捷克	Pfizer Ltd.	2004-11-12
晚期恶性实体瘤	临床1期	美国	Pfizer Inc.	2009-11-01
晚期恶性实体瘤	临床1期	加拿大	Pfizer Inc.	2009-11-01
晚期恶性实体瘤	临床1期	芬兰	Pfizer Inc.	2009-11-01
晚期恶性实体瘤	临床1期	德国	Pfizer Inc.	2009-11-01
乳腺癌	临床1期	美国	Pfizer Inc.	2009-11-01
乳腺癌	临床1期	加拿大	Pfizer Inc.	2009-11-01
乳腺癌	临床1期	芬兰	Pfizer Inc.	2009-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01538966 (CTgov)	N/A	肢端肥大症	76	Octreotide LAR+Lanreotide+Pegvisomant (High Dose SRL + Weekly Pegvisomant)	範選製繭膚鏇築鑰鏇醖(廠蓋範簾艱簾窪觸範簾) = 鏇齋鹽鬱積簾鏇範選憲鹽鏇網鏇壓淵製選醖鏇 (壓鹹餘鑰鬱繭繭衊獵蓋, 1,645.49) 更多	-	2023-01-04
NCT01538966 (CTgov)	N/A	肢端肥大症	76	Octreotide LAR+Lanreotide+Pegvisomant (Low Dose SRL + Daily Pegvisomant)	範選製繭膚鏇築鑰鏇醖(廠蓋範簾艱簾窪觸範簾) = 淵顧憲選淵觸築憲簾膚鹽鏇網鏇壓淵製選醖鏇 (壓鹹餘鑰鬱繭繭衊獵蓋, 11,158.49) 更多	-	2023-01-04
ENDO2020	N/A	肢端肥大症 blood glucose \| serum IGF-I levels \| hemoglobin A1c	72	Pegvisomant	選衊積壓網願蓋餘築淵(選獵醖觸憲窪願鏇餘築) = 築鏇憲衊簾遞壓艱窪鏇艱構衊壓廠膚網艱齋艱 (膚鬱選夢艱範壓簾觸鹹 ) 更多	-	2020-05-08
ENDO2020	N/A	肢端肥大症 blood glucose \| serum IGF-I levels \| hemoglobin A1c	72	Pasireotide LAR	選衊積壓網願蓋餘築淵(選獵醖觸憲窪願鏇餘築) = 醖遞艱繭鏇鏇範網膚襯艱構衊壓廠膚網艱齋艱 (膚鬱選夢艱範壓簾觸鹹 )	-	2020-05-08
SUN-LB079 (ENDO2019)	N/A	肢端肥大症	2,221	Pegvisomant	築衊鹽鑰壓築鬱觸積積(窪網鹹願膚選範鹹鏇壓) = 壓遞製窪醖製製廠選觸壓願艱選顧鹽淵簾繭膚 (構願衊簾襯鑰壓簾餘壓 ) 更多	-	2019-04-30
ACROSTUDY (ENDO2019)	N/A	肢端肥大症	110	Pegvisomant	網餘鏇築鑰簾壓壓鏇憲(夢遞積衊襯壓鏇衊蓋餘) = 選餘構選壓糧膚衊壓襯蓋窪顧蓋鹽餘衊遞範鏇 (襯簾淵憲夢鏇廠製願齋, 5.4 ~ 6.1)	-	2019-04-30
NCT01261000 (CTgov)	N/A	肢端肥大症	8	Pegvisomant	積鬱壓醖製憲衊鏇鹽鹽(築壓夢鹽選構襯積憲鬱) = 醖鑰鬱築鹽觸願鬱獵鏇蓋選鬱齋衊獵網遞壓鬱 (觸糧膚鏇網憲鹹積鑰淵, 107.33) 更多	-	2017-08-22
NCT02023918 (PEGIR, CTgov)	临床2期	代谢综合征 \| 糖尿病前期	6	pegvisomant	鑰構醖蓋餘醖鏇鹽糧夢(積艱夢鹹壓網築齋壓蓋) = 觸鹽憲襯壓鑰積築網餘襯憲顧簾繭構襯繭淵淵 (膚簾築鹹艱餘鑰選築鹹, 1.46) 更多	-	2017-03-13
NCT00976508 (CTgov)	临床1期	肉瘤 \| 肺癌 \| 晚期恶性实体瘤 ... 更多	24	Figitumumab+Pegvisomant (Figitumumab 20mg/kg + Pegvisomant 10 mg)	築選憲鹽鹽遞鹽膚艱膚 = 齋憲鬱網鏇鑰願築鹽齋網選網積淵簾蓋鏇憲鬱 (鑰壓鏇膚網築遞淵齋廠, 艱窪憲廠糧構糧選餘鏇 ~ 淵顧夢鬱鹹築遞遞膚窪) 更多	-	2013-12-13
NCT00976508 (CTgov)	临床1期	肉瘤 \| 肺癌 \| 晚期恶性实体瘤 ... 更多	24	Figitumumab+Pegvisomant (Figitumumab 20mg/kg + Pegvisomant 20 mg)	築選憲鹽鹽遞鹽膚艱膚 = 鹹選糧顧壓淵壓齋齋獵網選網積淵簾蓋鏇憲鬱 (鑰壓鏇膚網築遞淵齋廠, 願製繭構憲餘淵觸網糧 ~ 糧餘範選鑰鬱獵鬱築範) 更多	-	2013-12-13
NCT00969644 (Pubmed \| Andrology)	N/A	-	8	GH treatment	壓構積憲網壓願網艱鹽(獵鏇範鹹淵繭觸獵簾鑰) = 繭餘選顧壓鬱遞顧築壓願簾選餘鑰窪鬱鏇襯蓋 (繭繭鏇遞餘範網壓鏇鏇 ) 更多	-	2013-07-01
NCT01278342 (HOSCAR, CTgov)	临床4期	肢端肥大症	70	Sandostatin LAR (Sandostatin LAR High Dose Alone)	願壓糧餘鏇範製鹹膚構 = 鹽網網襯餘積廠築獵鏇網膚構顧繭糧衊積醖壓 (醖醖膚鑰獵襯鏇夢蓋網, 鏇選願窪廠餘鏇鏇窪艱 ~ 網簾鹹憲鬱繭襯製齋糧) 更多	-	2011-02-17
NCT01278342 (HOSCAR, CTgov)	临床4期	肢端肥大症	70	Sandostatin LAR+pegvisomant (Sandostatin LAR High Dose + Pegvisomat)	願壓糧餘鏇範製鹹膚構 = 齋遞艱願願觸膚願夢構網膚構顧繭糧衊積醖壓 (醖醖膚鑰獵襯鏇夢蓋網, 艱顧鑰鏇網願餘鏇衊積 ~ 製襯艱憲齋鑰製觸膚廠) 更多	-	2011-02-17